446 related articles for article (PubMed ID: 23953074)
1. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Bailey T
Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
[TBL] [Abstract][Full Text] [Related]
2. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
3. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
4. Integrating incretin-based therapy into type 2 diabetes management.
Brunton SA
J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
[No Abstract] [Full Text] [Related]
5. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
6. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
8. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
9. Increased priority for regimens involving incretin-based and insulin therapy.
Rodbard HW
J Fam Pract; 2013 Dec; 62(12 Suppl CME):S5-11. PubMed ID: 24340348
[TBL] [Abstract][Full Text] [Related]
10. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
11. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in incretin-based therapies.
Russell-Jones D; Gough S
Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
[TBL] [Abstract][Full Text] [Related]
13. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Wang Y; Zhao L; Huang Q; Peng Y
J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
[No Abstract] [Full Text] [Related]
14. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
15. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
16. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus.
Goldman-Levine JD
Pharmacotherapy; 2011 Dec; 31(12 Suppl):44S-53S. PubMed ID: 22122222
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Grunberger G
J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
[TBL] [Abstract][Full Text] [Related]
18. Add-on therapies to metformin for type 2 diabetes.
Shomali M
Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
[TBL] [Abstract][Full Text] [Related]
19. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
20. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
Boyle PJ; Freeman JS
J Am Osteopath Assoc; 2007 May; 107 Suppl():S10-6. PubMed ID: 17724013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
